We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

38 hedge funds and large institutions have $3.34M invested in NeuBase Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

32% more capital invested

Capital invested by funds: $2.52M → $3.34M (+$816K)

0% more funds holding

Funds holding: 38 → 38 (0)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $2K

Holders
38
Holders Change
–
Holders Change %
0%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
6
Closed
3
Calls
–
Puts
$2K
Net Calls
-$2K
Net Calls Change
+$3K

Top Buyers

1
WS
Wedbush Securities
California
+$295K
2
GBA
Garrison Bradford & Associates
New York
+$281K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$216K
4
Renaissance Technologies
Renaissance Technologies
New York
+$140K
5
VF
Virtu Financial
New York
+$22.7K

Top Sellers

1
SM
Sabby Management
Florida
-$361K
2
TRCT
Tower Research Capital (TRC)
New York
-$45K
3
Goldman Sachs
Goldman Sachs
New York
-$39K
4
Millennium Management
Millennium Management
New York
-$11K
5
CCB
Cutter & Co Brokerage
Missouri
-$4.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$812K +$216K +790 +39%
Renaissance Technologies
2
Renaissance Technologies
New York
$568K +$140K +513 +35%
GBA
3
Garrison Bradford & Associates
New York
$358K +$281K +1,030 +481%
WS
4
Wedbush Securities
California
$311K +$295K +1,080 New
BlackRock
5
BlackRock
New York
$301K +$819 +3 +0.3%
CC
6
Cannell & Co
New York
$211K – – –
SM
7
Sabby Management
Florida
$110K -$361K -1,323 -78%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$108K – – –
UCFA
9
United Capital Financial Advisors
Texas
$62K – – –
California Public Employees Retirement System
10
California Public Employees Retirement System
California
$57K – – –
LCM
11
Leisure Capital Management
California
$46K -$819 -3 -2%
Creative Planning
12
Creative Planning
Kansas
$44K +$2.18K +8 +6%
Northern Trust
13
Northern Trust
Illinois
$40K – – –
Neuberger Berman Group
14
Neuberger Berman Group
New York
$33K – – –
CCB
15
Cutter & Co Brokerage
Missouri
$28K -$4.1K -15 -13%
SM
16
Salzhauer Michael
$26K – – –
Bank of New York Mellon
17
Bank of New York Mellon
New York
$25K -$2.18K -8 -9%
VF
18
Virtu Financial
New York
$24K +$22.7K +83 New
UBS Group
19
UBS Group
Switzerland
$22K +$17.7K +65 +650%
Citadel Advisors
20
Citadel Advisors
Florida
$18K +$17.5K +64 New
HighTower Advisors
21
HighTower Advisors
Illinois
$17K – – –
FNBT
22
FineMark National Bank & Trust
Florida
$16K – – –
TSS
23
Two Sigma Securities
New York
$16K +$4.37K +16 +42%
Deutsche Bank
24
Deutsche Bank
Germany
$14K – – –
PNC Financial Services Group
25
PNC Financial Services Group
Pennsylvania
$14K – – –
1
2

NBSE Hedge Fund Activity: Q3 2017 in Review

38 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2017, worth a combined $3.34M — up 32% from $2.52M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new NBSE positions and 3 closed out — a net gain of 2 holders — while 8 added to existing stakes and 6 trimmed.

The largest buyer was Wedbush Securities, opening a new position worth an estimated $295K. The largest seller was Sabby Management, cutting an estimated $361K.

  • 38 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2017, unchanged from Q2 2017.
  • Funds reported $3.34M of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2017, up 32% quarter-over-quarter.
  • 5 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2017 and 3 closed out, a net change of +2 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q3 2017 was Wedbush Securities, an estimated $295K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2017 was Sabby Management, an estimated $361K sold.

Based on aggregated 13F filings for Q3 2017.